此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

CDK4/6 抑制剂剂量知识 (CDK) 研究

2026年10月30日 更新者:American Society of Clinical Oncology

比较老年转移性乳腺癌患者的口服药物剂量策略,以最大限度地提高耐受性并减少停药:CDK4/6 抑制剂剂量知识 (CDK) 研究

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs.

The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 60 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors.

Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing).

Note: Telehealth visits are allowed at any time per institutional guidelines. In addition, the study allows for remote consenting per institutional guidelines.

研究概览

详细说明

The CDK4/6 Inhibitor Dosing Knowledge Study (CDK Study) will study CDK4/6 inhibitor dosing regimens in patients 60 or older with Metastatic Breast Cancer (MBC). The overarching goal of this pragmatic, randomized trial is to compare an "indicated" dosing approach, as listed on the FDA-approved drug label, that starts at the full dose of a CDK4/6 inhibitor (palbociclib or ribociclib) with dose reduction based on tolerability versus a "titrated" dosing approach that starts at a lower dose of a CDK4/6 inhibitor and then titrates up to full dose as tolerated. CDK4/6 inhibitors will be given in combination with endocrine therapy (either an aromatase inhibitor (AI) or fulvestrant) based on the choice of the treating clinician.

The primary endpoint will be time to treatment discontinuation (TTD), defined as the time from randomization to last dose of the CDK4/6 inhibitor. The hypothesis is that starting low and escalating as tolerated will help older patients (> 60 years) stay on therapy longer. Eligibility criteria are broad to allow patients who are not typically included in clinical trials to participate, allowing for a more representative sample of participants. The investigators will conduct sub-group analyses based on age (60-64 years vs. 65-74 years vs. ≥75 years) and baseline frailty scores. This study builds upon the lessons learned from prior studies with CDK4/6 inhibitors. The investigators will augment the standard assessment of treatment toxicities assessed by the health care team with prospectively collected patient-reported outcomes data to better reflect how participants tolerate the different dosing approaches.

研究类型

介入性

注册 (估计的)

500

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Arizona
      • Chandler、Arizona、美国、85224
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Gilbert、Arizona、美国、85297
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Glendale、Arizona、美国、85306
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Goodyear、Arizona、美国、85395
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Mesa、Arizona、美国、85202
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Mesa、Arizona、美国、85206
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Phoenix、Arizona、美国、85028
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
      • Scottsdale、Arizona、美国、85260
        • 招聘中
        • Ironwood Cancer & Research Centers
        • 接触:
        • 首席研究员:
          • Sumeet Mendonca, MD
    • California
      • Eureka、California、美国、95501
        • 招聘中
        • Providence Medical Foundation
        • 接触:
        • 首席研究员:
          • Jarrod Holmes, MD
      • Santa Rosa、California、美国、95403
        • 招聘中
        • Providence Medical Foundation
        • 接触:
        • 首席研究员:
          • Jarrod Holmes, MD
    • Colorado
      • Aurora、Colorado、美国、80045
      • Denver、Colorado、美国、80206
      • Highlands Ranch、Colorado、美国、80129
    • Connecticut
      • Derby、Connecticut、美国、06418
        • 招聘中
        • Smilow Cancer Hospital Care Center - Derby
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Fairfield、Connecticut、美国、06824
        • 招聘中
        • Smilow Cancer Hospital Care Center - Fairfield
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Glastonbury、Connecticut、美国、06033
        • 招聘中
        • Smilow Cancer Hospital at Glastonbury
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Greenwich、Connecticut、美国、06830
        • 招聘中
        • Smilow Cancer Hospital Care Center - Greenwich
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Guilford、Connecticut、美国、06437
        • 招聘中
        • Smilow Cancer Hospital Care Center - Guilford
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Hartford、Connecticut、美国、06105
        • 招聘中
        • Smilow Cancer Hospital at Saint Francis
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • New Haven、Connecticut、美国、06510
        • 招聘中
        • Smilow Cancer Hospital - Yale New Haven Health
        • 接触:
        • 首席研究员:
          • Maryam Lustberg, MD, MPH
      • New Haven、Connecticut、美国、06510
        • 招聘中
        • Yale University/Yale Cancer Center/Yale School of Medicine
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • North Haven、Connecticut、美国、06473
        • 招聘中
        • Smilow Cancer Hospital Care Center - North Haven
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Torrington、Connecticut、美国、06790
        • 招聘中
        • Smilow Cancer Hospital Care Center - Torrington
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Trumbull、Connecticut、美国、06611
        • 招聘中
        • Smilow Cancer Hospital Care Center - Trumbull
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
      • Waterbury、Connecticut、美国、06708
        • 招聘中
        • Smilow Cancer Hospital Care Center - Waterbury
        • 首席研究员:
          • Maryam Lustberg
        • 接触:
      • Waterford、Connecticut、美国、06385
        • 招聘中
        • Smilow Cancer Hospital - Waterford
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
    • Florida
      • Miami、Florida、美国、33176
      • Plantation、Florida、美国、33324
        • 招聘中
        • Miami Cancer Institute
        • 首席研究员:
          • Reshma Mahtani, DO
        • 接触:
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory University Winship Cancer Institute
        • 首席研究员:
          • Kevin Kalinsky, MD
        • 接触:
      • Hinesville、Georgia、美国、31313
        • 招聘中
        • Liberty County Cancer Care
        • 接触:
        • 首席研究员:
          • Leonard Henry, MD
      • Pembroke、Georgia、美国、31321
        • 招聘中
        • Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite
        • 接触:
        • 首席研究员:
          • Leonard Henry, MD
      • Savannah、Georgia、美国、31405
        • 招聘中
        • Lewis Cancer and Research Pavilion
        • 接触:
        • 首席研究员:
          • Leonard Henry, MD
      • Statesboro、Georgia、美国、30458
        • 招聘中
        • Candler Medical Oncology Practice and Infusion
        • 接触:
        • 首席研究员:
          • Leonard Henry, MD
    • Indiana
      • Crown Point、Indiana、美国、46307
        • 招聘中
        • Northwest Cancer Center
        • 接触:
        • 首席研究员:
          • Michael Tallarico, MD
      • Dyer、Indiana、美国、46311
        • 招聘中
        • Northwest Cancer Center-Dyer
        • 接触:
        • 首席研究员:
          • Michael Tallarico, MD
      • Hobart、Indiana、美国、46342
        • 招聘中
        • St. Mary Medical Center
        • 接触:
        • 首席研究员:
          • Michael Tallarico, MD
      • Munster、Indiana、美国、46321
        • 招聘中
        • Powers Health Cancer Research Foundation
        • 接触:
        • 首席研究员:
          • Michael Tallarico, MD
      • Valparaiso、Indiana、美国、46383
        • 招聘中
        • Northwest Cancer Center
        • 接触:
        • 首席研究员:
          • Michael Tallarico, MD
    • Kansas
      • Westwood、Kansas、美国、66205
        • 招聘中
        • The University of Kansas Cancer Center
        • 接触:
        • 首席研究员:
          • Ryan Rader, MD
    • Maine
      • Augusta、Maine、美国、04330
        • 招聘中
        • The Jackson Laboratory (JAX) - Harold Alfond Center for Cancer Care
        • 接触:
        • 首席研究员:
          • Erin Adler, DO
      • Brewer、Maine、美国、04412
        • 招聘中
        • The Jackson Laboratory (JAX) - Northern Light Cancer Care
        • 接触:
        • 首席研究员:
          • Sarah Sinclair, DO
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Dana-Farber Cancer Institute
        • 首席研究员:
          • Erica Mayer, MD
        • 接触:
          • Call
          • 电话号码:877-338-7425
      • Foxborough、Massachusetts、美国、02035
        • 招聘中
        • Dana-Farber Brigham Cancer Center Foxborough
        • 接触:
          • 877-DF-TRIAL
          • 电话号码:877-338-7425
        • 首席研究员:
          • Sudha Bolla, MD
      • Methuen、Massachusetts、美国、01844
        • 招聘中
        • Dana-Farber Cancer Institute Merrimack Valley
        • 接触:
          • 877-DF-TRIAL
          • 电话号码:877-338-7425
        • 首席研究员:
          • Ankur Mehta, MD
      • Milford、Massachusetts、美国、01757
        • 招聘中
        • Dana-Farber Brigham Cancer Center at Milford Regional Medical Center
        • 首席研究员:
          • Natalie Sinclair, MD
        • 接触:
          • 877-DF-TRIAL
          • 电话号码:8773387425
      • Weymouth、Massachusetts、美国、02190
        • 招聘中
        • Dana-Farber Brigham Cancer Center at South Shore Health
        • 首席研究员:
          • James Stoeckle, MD
        • 接触:
          • 877-DF-TRIAL
          • 电话号码:8773387425
    • New Hampshire
      • Londonderry、New Hampshire、美国、03053
        • 招聘中
        • Dana-Farber/New Hampshire Oncology-Hematology
        • 首席研究员:
          • Jeanna Walsh, MD
        • 接触:
          • 877-DF-TRIAL
          • 电话号码:877-338-7425
    • New Jersey
      • Englewood、New Jersey、美国、07631
        • 招聘中
        • Englewood Hospital
        • 首席研究员:
          • Jill Morrison, MD
        • 接触:
      • Pennington、New Jersey、美国、08534
        • 招聘中
        • Capital Health Medical Center - Hopewell
        • 接触:
        • 首席研究员:
          • Pamella Crilley, DO
      • Plainsboro、New Jersey、美国、08536
    • New Mexico
      • Albuquerque、New Mexico、美国、87110
        • 招聘中
        • Presbyterian Kaseman Hospital
        • 首席研究员:
          • Bernard Tawfik, MD
        • 接触:
      • Albuquerque、New Mexico、美国、87109
        • 招聘中
        • Lovelace Women's Hospital
        • 首席研究员:
          • Bernard Tawfik, MD
        • 接触:
      • Albuquerque、New Mexico、美国、87102
        • 招聘中
        • Lovelace Medical Center - Saint Joseph Square
        • 首席研究员:
          • Bernard Tawfik, MD
        • 接触:
      • Albuquerque、New Mexico、美国、87131
        • 招聘中
        • The University of New Mexico Comprehensive Cancer Center
        • 首席研究员:
          • Bernard Tawfik, MD
        • 接触:
      • Las Cruces、New Mexico、美国、88011
        • 招聘中
        • Memorial Medical Center
        • 首席研究员:
          • Bernard Tawfik, MD
        • 接触:
      • Rio Rancho、New Mexico、美国、87124
        • 招聘中
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
        • 首席研究员:
          • Bernard Tawfik, MD
        • 接触:
    • North Carolina
      • Albemarle、North Carolina、美国、28001
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Charlotte、North Carolina、美国、28204
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Charlotte、North Carolina、美国、28210
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Charlotte、North Carolina、美国、28211
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Charlotte、North Carolina、美国、28262
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Charlotte、North Carolina、美国、28277
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Concord、North Carolina、美国、28025
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Forest City、North Carolina、美国、28043
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Gastonia、North Carolina、美国、28054
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Huntersville、North Carolina、美国、28078
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Lincolnton、North Carolina、美国、28092
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Matthews、North Carolina、美国、28104
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Monroe、North Carolina、美国、28112
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
      • Shelby、North Carolina、美国、28150
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • 招聘中
        • University of Cincinnati Medical Center
        • 接触:
        • 首席研究员:
          • Mahmoud Charif, MD
      • West Chester、Ohio、美国、45069
        • 招聘中
        • University of Cincinnati Medical Center - West Chester Hospital
        • 接触:
        • 首席研究员:
          • Mahmoud Charif, MD
    • Pennsylvania
      • Lancaster、Pennsylvania、美国、17601
        • 招聘中
        • Penn Medicine - Lancaster General Hospital
        • 接触:
        • 首席研究员:
          • Ramy Sedhom, MD
      • Newton、Pennsylvania、美国、18940
        • 招聘中
        • Capital Health Hematology Oncology Specialists
        • 接触:
        • 首席研究员:
          • Pamella Crilley, DO
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Penn Medicine - Perelman Center for Advanced Medicine
        • 首席研究员:
          • Ramy Sedhom, MD
        • 接触:
      • Philidelphia、Pennsylvania、美国、19106
        • 招聘中
        • Penn Medicine - Pennsylvania Hospital
        • 接触:
        • 首席研究员:
          • Ramy Sedhorn, MD
      • West Chester、Pennsylvania、美国、19380
    • Rhode Island
      • Westerly、Rhode Island、美国、02891
        • 招聘中
        • Smilow Cancer Hospital - Westerly
        • 首席研究员:
          • Maryam Lustberg, MD
        • 接触:
    • South Carolina
      • Bluffton、South Carolina、美国、29910
        • 招聘中
        • St. Joseph's Candler Bluffton Campus
        • 接触:
        • 首席研究员:
          • Leonard Henry, MD
      • Hilton Head Island、South Carolina、美国、29926
        • 招聘中
        • SC Cancer Specialists - Hilton Head at St. Joseph's/Candler
        • 首席研究员:
          • Leonard Henry, MD
        • 接触:
      • Rock Hill、South Carolina、美国、29732
        • 招聘中
        • Levine Cancer Institute
        • 首席研究员:
          • Neelam Desai, MD
        • 接触:
    • Tennessee
      • Memphis、Tennessee、美国、38120
        • 招聘中
        • Baptist Memorial Healthcare
        • 首席研究员:
          • Glenn Roma, MD
        • 接触:
    • Washington
      • Bellevue、Washington、美国、98004
        • 招聘中
        • Fred Hutchinson Cancer Center at Overlake Cancer Center
        • 首席研究员:
          • Jennifer Specht, MD
        • 接触:
          • Jennifer Specht, MD
          • 电话号码:206-606-6889
          • 邮箱:jspecht@uw.edu
      • Bonney Lake、Washington、美国、98391
        • 招聘中
        • Northwest Medical Specialties
        • 首席研究员:
          • Frank Senecal, MD
        • 接触:
      • Federal Way、Washington、美国、98003
        • 招聘中
        • Northwest Medical Specialties
        • 首席研究员:
          • Frank Senecal, MD
        • 接触:
      • Gig Harbor、Washington、美国、98332
        • 招聘中
        • Northwest Medical Specialties
        • 首席研究员:
          • Frank Senecal, MD
        • 接触:
      • Kirkland、Washington、美国、98034
        • 招聘中
        • Fred Hutchinson Cancer Center at EvergreenHealth
        • 首席研究员:
          • Jennifer Specht, MD
        • 接触:
          • Jennifer Specht, MD
          • 电话号码:206-606-6889
          • 邮箱:jspecht@uw.edu
      • Olympia、Washington、美国、98502
        • 招聘中
        • Northwest Medical Specialties
        • 首席研究员:
          • Frank Senecal, MD
        • 接触:
      • Puyallup、Washington、美国、98373
        • 招聘中
        • Northwest Medical Specialties
        • 首席研究员:
          • Frank Senecal, MD
        • 接触:
      • Seattle、Washington、美国、98109
        • 招聘中
        • Fred Hutchinson Cancer Center
        • 首席研究员:
          • Jennifer Specht, MD
        • 接触:
          • Jennifer Specht, MD
          • 电话号码:206-606-6889
          • 邮箱:jspecht@uw.edu
      • Seattle、Washington、美国、98133
        • 招聘中
        • Fred Hutchinson Cancer Center at University of Washington-Northwest
        • 首席研究员:
          • Jennifer Specht, MD
        • 接触:
          • Jennifer Specht, MD
          • 电话号码:206-606-6889
          • 邮箱:jspecht@uw.edu
      • Tacoma、Washington、美国、98405
        • 招聘中
        • Northwest Medical Specialties
        • 首席研究员:
          • Frank Senecal, MD
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Hormone receptor positive (HR+) HER2 negative metastatic breast cancer. Cut-off values for positive/negative staining should be as per standard practice in accordance with ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines. Verification of histology is preferred at the time of recurrence and where not possible or necessary in the judgment of the treating physician, the study will accept histology from the initial diagnosis.

  2. Candidate for planned endocrine therapy in combination with 1st use of palbociclib or ribociclib, in the metastatic setting. The planned endocrine partner can be an aromatase inhibitor (letrozole, anastrozole, exemestane) or fulvestrant, selected through patient/provider choice.

  3. Aged 60 years or older

  4. Adequate bone marrow and organ function. Laboratory values must be within normal institutional limits, or within ranges as indicated below, or demonstrate minor abnormalities that are deemed clinically non-significant by the investigator.

    • Absolute neutrophil count ≥ 1,000/µL
    • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (participants with documented Gilbert's disease are allowed total bilirubin up to 5X ULN)
    • AST (SGOT)/ALT (SGPT) <3 x institutional ULN, or ≤ 5 x ULN for subjects with documented metastatic disease to the liver.
  5. Baseline QTc ≤ 480 ms (only for ribociclib patients)

  6. Ability to understand and the willingness to provide informed consent. Note: Remote consent is allowed per institutional guidelines.

Exclusion Criteria:

  1. Previous treatment with a CDK4/6 inhibitor for metastatic breast cancer, or previous treatment within the past 12 months with a CDK4/6 inhibitor in the neo/adjuvant breast cancer setting.
  2. Received greater than 60 days (in the metastatic setting) of the specific endocrine therapy agent planned as partner to the CDK4/6 inhibitor in the study at the time of randomization.
  3. Known history of intolerance or allergy to the planned agents used in this trial.
  4. Uncontrolled intercurrent illness that, as evaluated by the treating clinician, would hinder compliance with study requirements.
  5. Concurrent therapy with other investigational agents or anticancer therapy beyond aromatase inhibitors or fulvestrant. Note: radiation is allowed at any time.
  6. Rapidly progressive brain metastases. Note: only applies to patients with known brain metastases. Brain imaging not required for enrollment.
  7. Active or chronic Hepatitis B or C are eligible provided they meet liver function laboratory criteria and are not on medication with a known interaction with the study agents.
  8. Current use of drugs that have known potential to prolong the QT interval (e.g., antiarrhythmic drugs), for patients on ribociclib. Note: If concomitant use cannot be avoided, monitor ECG when initiating, during concomitant use, and as clinically indicated. Refer to crediblemeds.org as a resource.
  9. Prior or concurrent malignancies that are undergoing active treatment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1: Indicated Dose

Arm 1 of the study is the indicated dosing regimen, provided in the FDA approved drug label: participants will start cycle 1 with either 125mg dose of palbociclib or 600mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant).

Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)

Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)

实验性的:Arm 2: Titrated Dose

Arm 2 is the titrated dosing regimen: participants will start cycle 1 with either 100 mg or 75 mg dose of palbociclib or 400 mg or 200 mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant). For cycle 2 and for subsequent cycles, escalation to the indicated dose will be based on treatment tolerance.

Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.

Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time to Treatment Discontinuation (TTD)
大体时间:up to 48 months

Our primary outcome is time to CDK4/6 inhibitor discontinuation (TTD): the number of days between randomization and the last day the patient takes any dose of the same CDK4/6 inhibitor (regardless of drug holds, dose changes

up to 48 months

次要结果测量

结果测量
措施说明
大体时间
Toxicity (grade 3-4 AEs)
大体时间:up to 48 months

Assessed in each arm of the study and study drug

up to 48 months
Event-Free survival (EFS)
大体时间:up to 48 months

Assessed in each arm of the study and study drug

up to 48 months
Quality of life assessed by patient reported outcomes
大体时间:up to 48 months

PROMIS-29 (3 domains of 12 questions, physical function, fatigue, participation in social activities), FACT-G Item GP5 (1 question)

up to 48 months
Time to dose reduction and escalation
大体时间:up to 48 months

For titrated arm. Assessed in each arm of the study and study drug

up to 48 months
Reason for not escalating
大体时间:up to 48 months

Assessed in each arm of the study and study drug

up to 48 months
Treatment received (missed doses, cumulative dose, etc.)
大体时间:up to 48 months

Assessed in each arm of the study and study drug

up to 48 months
Healthcare utilization (ED visits, hospital admissions, etc.)
大体时间:up to 48 months

ED visits, hospital admissions, etc., assessed in each arm of the study and study drug

up to 48 months
Body Mass Index
大体时间:up to 48 months

weight and height will be combined to report BMI in kg/m^2

up to 48 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Julie Gralow, MD、American Society of Clinical Oncology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月29日

初级完成 (估计的)

2028年8月31日

研究完成 (估计的)

2028年9月1日

研究注册日期

首次提交

2024年4月8日

首先提交符合 QC 标准的

2024年4月17日

首次发布 (实际的)

2024年4月22日

研究记录更新

最后更新发布 (实际的)

2026年11月2日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • Pro00075309

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅